erlotinib hydrochloride has been researched along with tyrosine in 16 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (tyrosine) | Trials (tyrosine) | Recent Studies (post-2010) (tyrosine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 44,273 | 846 | 8,225 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, LD; Baker, DA; Barbacci, EG; Davis, JA; Doty, JL; Iwata, KK; Morin, MJ; Moyer, JD; Pollack, VA; Pustilnik, LR; Savage, DM; Sloan, DE; Smolarek, TA; Tsaparikos, KE; Vaidya, MP | 1 |
| Bacus, S; Brattain, MG; deGraffenried, L; Hammond, LA; Hidalgo, M; Kreisberg, JI; Malik, SN; Rizzo, J; Rowinsky, EK; Siu, LL | 1 |
| Abbott, DW; Asara, JM; Tigno-Aranjuez, JT | 1 |
| Cheon, GJ; Choi, CM; Choi, SJ; Choi, YJ; Jeon, BS; Kim, CH; Kim, HR; Lee, JC; Rho, JK; Woo, SK | 1 |
| Cavenee, WK; Furnari, F; Gonias, SL; Hu, J; Jo, M; VandenBerg, SR | 1 |
| Bachoo, RM; Cavenee, WK; Dang, J; DePinho, RA; Fenton, TR; Furnari, FB; Inda, MM; Iwanami, A; James, CD; Kuga, D; Marie, SK; Mischel, PS; Nathanson, D; Oba-Shinjo, SM; Ponte de Albuquerque, C; Tanaka, K; Uno, M; Vandenberg, SR; Wykosky, J; Yang, H; Zhou, H | 1 |
| Augustin, A; Avila, D; Berrera, M; Ebeling, M; Golling, S; Lamerz, J; Langen, H; Tzouros, M | 1 |
| Altiok, S; Doshi, P; Fulp, W; Haura, EB; Sasser, K; Smith, MA; Song, L | 1 |
| De Maria, R; Duranti, E; Eramo, A; Fecchi, K; Gallo, E; Milella, M; Mottolese, M; Pilozzi, E; Policicchio, E; Salvati, V; Sette, G; Tartaglia, M; Visca, P | 1 |
| Abe, Y; Adachi, J; Nagano, M; Tada, A; Tomonaga, T | 1 |
| Awasthi, S; Bansal, M; Belkina, N; Biswas, R; Califano, A; Chaerkady, R; Charles Jacob, HK; Cultraro, CM; Gao, S; Guha, U; Kashyap, MK; Kirkali, G; Maity, T; Marimuthu, A; Pandey, A; Pitts, S; Singh, S; Venugopalan, A; Zhang, X | 1 |
| Choe, SW; Kim, MJ; Kim, YH; Lee, YJ; P Oh, S; Sprecher, D | 1 |
| Abdulla, DSY; Brandes, V; Büttner, R; Drzezga, A; Fischer, R; Galldiks, N; Grau, S; Kobe, C; Kunze, S; Merkelbach-Bruse, S; Michels, S; Nogova, L; Persigehl, T; Riedel, R; Ruge, M; Scheffler, M; Wolf, J | 1 |
| Chatterjee, A; Gowda, H; Jain, AP; Keshava Prasad, TS; Kumar, M; Mathur, PP; Nanjappa, V; Patel, K; Pinto, S; Radhakrishnan, A; Raja, R; Sidransky, D | 1 |
| Baitharu, I; Behera, AK; Chopdar, KS; Dash, GC; Meher, RK; Mir, SA; Mohanta, PP; Mohapatra, PK; Nayak, B; Raval, MK | 1 |
| Chen, Y; Dong, Q; Fu, Y; Hu, B; Li, J; Li, TE; Qin, LX; Qin, W; Ren, X; Shen, X; Su, Y; Sun, H; Wang, CQ; Wang, S; Wang, X; Wang, Z; Zhang, Z; Zheng, Y; Zhu, L; Zou, T | 1 |
16 other study(ies) available for erlotinib hydrochloride and tyrosine
| Article | Year |
|---|---|
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Phosphorylation; Phosphotyrosine; Polypharmacy; Quinazolines; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine | 1999 |
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Mitogen-Activated Protein Kinases; Neoplasms; Quinazolines; Signal Transduction; Skin; Tyrosine; Up-Regulation | 2003 |
Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Cells, Cultured; Cytokines; Enzyme Activation; Erlotinib Hydrochloride; Gefitinib; Gene Knockout Techniques; HEK293 Cells; HT29 Cells; Humans; Mice; Nod2 Signaling Adaptor Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination | 2010 |
Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
Topics: Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mutation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Signal Transduction; Silybin; Silymarin; Tyrosine; Xenograft Model Antitumor Assays | 2010 |
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Topics: Animals; Antibiotics, Antineoplastic; Brain; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Immunoblotting; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, Urokinase Plasminogen Activator; RNA Interference; STAT5 Transcription Factor; Transplantation, Heterologous; Tyrosine | 2011 |
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Topics: Animals; Astrocytes; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Mice, Mutant Strains; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine | 2012 |
Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics.
Topics: Breast Neoplasms; Cell Line, Tumor; Chromatography, Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Isotope Labeling; Neoplasm Proteins; Phosphopeptides; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tandem Mass Spectrometry; Tyrosine | 2013 |
Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models, Animal; Erlotinib Hydrochloride; Female; Fibroblasts; Humans; Interleukin-6; Lung Neoplasms; Mice; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Serine; STAT3 Transcription Factor; Tyrosine | 2014 |
Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Staging; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-2; Signal Transduction; Tyrosine; Xenograft Model Antitumor Assays | 2015 |
Deep Phosphotyrosine Proteomics by Optimization of Phosphotyrosine Enrichment and MS/MS Parameters.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatography, Liquid; Databases, Protein; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Mitogen-Activated Protein Kinase 13; Neoplasm Proteins; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proteomics; Signal Transduction; Tandem Mass Spectrometry; Tyrosine | 2017 |
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Isotope Labeling; Lung Neoplasms; Mass Spectrometry; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proteomics; Quinazolines; Reproducibility of Results; Signal Transduction; Tyrosine | 2017 |
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing | 2017 |
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Positron-Emission Tomography; Tyrosine | 2019 |
How to Achieve Therapeutic Response in Erlotinib-Resistant Head and Neck Squamous Cell Carcinoma? New Insights from Stable Isotope Labeling with Amino Acids in Cell Culture-Based Quantitative Tyrosine Phosphoproteomics.
Topics: Amino Acids; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Isotope Labeling; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Tyrosine | 2021 |
In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Docking Simulation; Molecular Structure; Noscapine; Protein Kinase Inhibitors; Quinazolinones; Structure-Activity Relationship; Tyrosine | 2022 |
Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.
Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholesterol; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; STAT3 Transcription Factor; Tyrosine | 2022 |